22.692 articles found

LEVODOPA PRODRUG MESYLATE, COMPOSITIONS THEREOF, AND USES THEREOF

XIANG JIA-NING, DAI XUEDONG, ZHOU CINDY X, LI JIANHUA, NGUYEN MARK Q.

· 2011-01-20

Efficacy, safety, and patient preference of monoamine oxidase B inhibitors in the treatment of Parkinson's disease.

Robottom BJ.

Patient Prefer Adherence · 2011-01-20

DOI: 10.2147/ppa.s11182PMID: 21423589

COMPOSITION COMPRISING GDNF AND TGF-?1 AND USE THEREOF FOR THE TREATMENT OF A NEUROLOGICAL DISEASE

FERNANDEZ ESPEJO EMILIO, GONZALEZ APARICIO RAMIRO JOSE.

· 2011-01-19

Oral pharmacological treatment of X-linked dystonia parkinsonism: successes and failures.

Jamora RD, Diesta CC, Pasco PM, Lee LV.

Int J Neurosci · 2011-01-19

DOI: 10.3109/00207454.2010.544433PMID: 21244304

Chronic, systemic treatment with a metabotropic glutamate receptor 5 antagonist produces anxiolytic-like effects and reverses abnormal firing activity of projection neurons in the basolateral nucleus of the amygdala in rats with bilateral 6-OHDA lesions.

Chen L, Liu J, Ali U, Gui ZH, Hou C, Fan LL, Wang Y, Wang T.

Brain Res Bull · 2011-01-19

DOI: 10.1016/j.brainresbull.2011.01.005PMID: 21255635

METHODS FOR THE DIAGNOSIS AND TREATMENT OF PARKINSON'S DISEASE

CHUNG CHEE YEUN, ISACSON OLE.

· 2011-01-18

NON-INVASIVE TREATMENT OF NEURODEGENERATIVE DISEASES

SIMON BRUCE, ERRICO JOSEPH P, RAFFLE JOHN T.

· 2011-01-12

TREATMENT OF CNS DISORDERS ASSOCIATED WITH MUTATIONS IN GENES ENCODING LYSOSOMAL ENZYMES

WUSTMAN BRANDON.

· 2011-01-07

Treatment of severe drooling with botulinum toxin in amyotrophic lateral sclerosis and Parkinson's disease: efficacy and possible mechanisms.

Møller E, Karlsborg M, Bardow A, Lykkeaa J, Nissen FH, Bakke M.

Acta Odontol Scand · 2011-01-03

DOI: 10.3109/00016357.2010.545035PMID: 21198339

High-Throughput and High-Content Screening for Huntington’s Disease Therapeutics

Varma H, Lo DC, Stockwell BR.

· 2011-01-01

PMID: 21882410

The association between adherence to levodopa/carbidopa/entacapone therapy and healthcare utilization and costs among patients with Parkinson's disease: a retrospective claims-based analysis.

Delea TE, Thomas SK, Hagiwara M.

CNS Drugs · 2011-01-01

DOI: 10.2165/11538970-000000000-00000PMID: 21128694

Erythrocytes catechol-o-methyl transferase activity is up-regulated after a 3-month treatment by entacapone in parkinsonian patients.

Maltête D, Cottard AM, Mihout B, Costentin J.

Clin Neuropharmacol · 2011-01-01

DOI: 10.1097/wnf.0b013e318205dff7PMID: 21164341